Publications & Presentations

December 18, 2025

MPROVE-DiCE, a 2-Part, Open-Label, Phase 2a Trial Evaluating the Safety and Effectiveness of Ninerafaxstat in Patients With Cardiometabolic Syndromes

March 29, 2025

ACC.25 Effects of Ninerafaxstat on myocardial energetics, exercise capacity, and cardiac function in heart failure with preserved ejection fraction, Type 2 Diabetes and Obesity- a Phase 2a clinical trial

August 31, 2024

ESC Congress 2024 IMPROVE-ISCHEMIA Presentation

April 8, 2024

ACC.24 Late-Breaking IMPROVE-HCM Presentation

April 8, 2024

Safety and Efficacy of Metabolic Modulation With Ninerafaxstat in Patients With Nonobstructive Hypertrophic Cardiomyopathy

December 5, 2022

Ninerafaxstat to Provide Optimal Ventricular Energetics in HCM: IMPROVE-HCM

August 26, 2022

IMPROVE DiCE: A Phase 2a Trial Investigating Ninerafaxstat - A Novel Cardiac Mitotrope for the treatment of Diabetic Cardiomyopathy

July 5, 2021

Phase 1 safety and tolerability study of IMB-1018972, a novel oral modulator of substrate utilization designed to improve cardiac metabolic efficiency and bioenergetics